Benazepril and the kidney: new indication.  No better than the other ACE inhibitors.
(1) The action of benazepril on the progression of renal failure in non diabetic patients has been assessed in a comparative placebo-controlled trial involving nearly 600 patients, most of whom were hypertensive. (2) This trial showed a statistically significant slowing of renal failure on benazepril, but the possibility of bias casts doubts on this conclusion; moreover, excess deaths occurred in the benazepril group. (3) Currently, the slowing of the progression of renal failure is not a valid basis for choosing between angiotensin-converting-enzyme inhibitors for non diabetic hypertensive patients with renal failure.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D001552:Benzazepines; D002986:Clinical Trials as Topic; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D005602:France; D006801:Humans; D006973:Hypertension; D051437:Renal Insufficiency / Q000188:drug therapy*; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D001552:Benzazepines